Tags

Type your tag names separated by a space and hit enter

Efficacy of a motilin receptor agonist (ABT-229) for the treatment of gastro-oesophageal reflux disease.
Aliment Pharmacol Ther 2002; 16(4):749-57AP

Abstract

BACKGROUND

ABT-229 is a potent motilin agonist without significant antibiotic activity. It has been shown to improve gastric emptying in humans and to increase lower oesophageal sphincter pressure in cats.

AIM

To assess the efficacy of four different doses of ABT-229 (1.25 mg, 2.5 mg, 5 mg, 10 mg b.d.) compared to placebo in the treatment of gastro-oesophageal reflux disease, and to determine its safety in patients with gastro-oesophageal reflux disease.

METHODS

In a double-blind, multicentre study, 324 patients with heartburn were randomized to receive four different doses of ABT-229 or placebo for 8 weeks. The efficacy was evaluated by Patient Symptom Questionnaire, daily diary, endoscopy and global evaluation of efficacy.

RESULTS

There were no statistically significant improvement scores for any of the ABT-229 treatment groups vs. the placebo group in any of the efficacy parameters. Reflux symptom scores were significantly worse after treatment in the dyspeptic group. ABT-229 appeared to be well tolerated and safe in total daily doses up to 20 mg.

CONCLUSION

ABT-229 appears to have limited, if any, clinical utility in the treatment of gastro-oesophageal reflux disease.

Authors+Show Affiliations

Lynn Institute for Healthcare Research, Oklahoma City, OK 73112, USA.No affiliation info availableNo affiliation info availableNo affiliation info availableNo affiliation info availableNo affiliation info availableNo affiliation info availableNo affiliation info availableNo affiliation info availableNo affiliation info availableNo affiliation info available

Pub Type(s)

Clinical Trial
Comparative Study
Journal Article
Multicenter Study
Randomized Controlled Trial
Research Support, Non-U.S. Gov't

Language

eng

PubMed ID

11929393

Citation

Chen, C L., et al. "Efficacy of a Motilin Receptor Agonist (ABT-229) for the Treatment of Gastro-oesophageal Reflux Disease." Alimentary Pharmacology & Therapeutics, vol. 16, no. 4, 2002, pp. 749-57.
Chen CL, Orr WC, Verlinden MH, et al. Efficacy of a motilin receptor agonist (ABT-229) for the treatment of gastro-oesophageal reflux disease. Aliment Pharmacol Ther. 2002;16(4):749-57.
Chen, C. L., Orr, W. C., Verlinden, M. H., Dettmer, A., Brinkhoff, H., Riff, D., ... Mack, R. J. (2002). Efficacy of a motilin receptor agonist (ABT-229) for the treatment of gastro-oesophageal reflux disease. Alimentary Pharmacology & Therapeutics, 16(4), pp. 749-57.
Chen CL, et al. Efficacy of a Motilin Receptor Agonist (ABT-229) for the Treatment of Gastro-oesophageal Reflux Disease. Aliment Pharmacol Ther. 2002;16(4):749-57. PubMed PMID: 11929393.
* Article titles in AMA citation format should be in sentence-case
TY - JOUR T1 - Efficacy of a motilin receptor agonist (ABT-229) for the treatment of gastro-oesophageal reflux disease. AU - Chen,C L, AU - Orr,W C, AU - Verlinden,M H, AU - Dettmer,A, AU - Brinkhoff,H, AU - Riff,D, AU - Schwartz,S, AU - Soloway,R D, AU - Krause,R, AU - Lanza,F, AU - Mack,R J, PY - 2002/4/4/pubmed PY - 2002/9/7/medline PY - 2002/4/4/entrez SP - 749 EP - 57 JF - Alimentary pharmacology & therapeutics JO - Aliment. Pharmacol. Ther. VL - 16 IS - 4 N2 - BACKGROUND: ABT-229 is a potent motilin agonist without significant antibiotic activity. It has been shown to improve gastric emptying in humans and to increase lower oesophageal sphincter pressure in cats. AIM: To assess the efficacy of four different doses of ABT-229 (1.25 mg, 2.5 mg, 5 mg, 10 mg b.d.) compared to placebo in the treatment of gastro-oesophageal reflux disease, and to determine its safety in patients with gastro-oesophageal reflux disease. METHODS: In a double-blind, multicentre study, 324 patients with heartburn were randomized to receive four different doses of ABT-229 or placebo for 8 weeks. The efficacy was evaluated by Patient Symptom Questionnaire, daily diary, endoscopy and global evaluation of efficacy. RESULTS: There were no statistically significant improvement scores for any of the ABT-229 treatment groups vs. the placebo group in any of the efficacy parameters. Reflux symptom scores were significantly worse after treatment in the dyspeptic group. ABT-229 appeared to be well tolerated and safe in total daily doses up to 20 mg. CONCLUSION: ABT-229 appears to have limited, if any, clinical utility in the treatment of gastro-oesophageal reflux disease. SN - 0269-2813 UR - https://www.unboundmedicine.com/medline/citation/11929393/Efficacy_of_a_motilin_receptor_agonist__ABT_229__for_the_treatment_of_gastro_oesophageal_reflux_disease_ L2 - https://onlinelibrary.wiley.com/resolve/openurl?genre=article&sid=nlm:pubmed&issn=0269-2813&date=2002&volume=16&issue=4&spage=749 DB - PRIME DP - Unbound Medicine ER -